Table 2.
Treatment, severity, and outcome of COVID-19
| Factor | Value |
|---|---|
| Patients using neutralizing antibody, n (%) | |
| Sotrovimab | 24 (54.5) |
| Imdevimab/casirivimab | 22 (50.0) |
| Tixagevimab/cilgavimab (treatment) | 4 (9.1) |
| Tixagevimab/cilgavimab (prophylaxis) | 6 (13.6) |
| Patients using antiviral, n (%) | |
| Remdesivir | 24 (54.5) |
| Molnupiravir | 25 (56.8) |
| Nirmatrelvir/ritonavir | 23 (52.3) |
| Ensitrelvir | 17 (38.6) |
| Combination therapy (2 antivirals) | 22 (50.0) |
| First treated with combination therapy | 9 (20.5) |
| Multiple antiviral regimens | 27 (61.4) |
| Duration of antiviral, days, (range) | 10 (10–20) |
| Patients using corticosteroid, n (%) | 18 (40.9) |
| Patients using baricitinib, n (%) | 8 (18.2) |
| Period since onset to viral shedding, days, (range) | 28 (19–38) |
| Positive nucleocapsid protein antibody at viral shedding, n (%) | 8 (18.2) |
| Severity of patients with COVID-19, n (%) | |
| Moderate | 26 (59.1) |
| Severe | 16 (36.4) |
| Critical | 2 (4.5) |
| Mortality, n (%) | 0 (0) |